PCSK9 and myocardial infarction: The primary therapeutic indications for these drugs include hypercholesterolemia, coronary artery disease, myocardial infarction, and hyperlipidaemia—conditions collectively classified under cardiovascular diseases—all of which target and inhibit PCSK9 activity.